Mainou M, Alsadhan M, Tsapa K, Visram A, Mian H, Popat R, Mai EK, Chakraborty R, Al Hadidi S, Mohan M, Szabo A, Van Oekelen O, Cliff ERS, Mohyuddin GR - Journal of the National Cancer Institute
- Research Publications
- Regulation and Clinical Evidence
Summary:
Across 123 randomized myeloma trials, studies were far less likely to succeed when overall survival was the primary endpoint and when enrolled populations were older. Endpoint selection and trial population design strongly influence apparent trial success and should be explicitly weighed by sponsors and regulators.
VIEW SOURCE
Recent Work from PORTAL
How Congress Can Fix Expert Advisory Committees
Daval CJR, Kesselheim AS - STAT
- Commentary & Opinion
- Regulation and Clinical Evidence
International Regulatory Status and Reimbursement Recommendations of Haematological Malignancy Drugs Withdrawn from the FDA Accelerated Approval Pathway
Mulsant SS, Kesselheim AS, Naci H - Journal of Cancer Policy
- Research Publications
- Price, Value, and Access
- Regulation and Clinical Evidence
The Impact of Semantics in Medicines Regulation
Costa E, Kesselheim AS - Journal of Law, Medicine, & Ethics
- Commentary & Opinion
- Innovation Incentives and Competition
- Regulation and Clinical Evidence
Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115
©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.